10 October 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Notice of Results
Analyst Briefing and Investor Presentation
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, will announce its full year results for the year ended 30 June 2025 on Tuesday, 14 October 2025 and hold the following analyst briefing and investor presentation.
Analyst briefing
An online briefing for analysts will be hosted by Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer, at 9.30 am on Tuesday, 14 October 2025, to review the full year results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at sarah@northstarcommunications.co.uk.
Investor presentation
An investor presentation to cover the full year results will be held at 2.00 pm on Tuesday, 14 October 2025.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited.
- Ends -
For further information, please contact:
| Aptamer Group plc Dr Arron Tolley, Chief Executive Officer | +44 (0) 1904 217 404 |
| SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott | +44 (0) 20 3368 3550 |
| Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker | +44 (0) 20 3657 0050 |
| Northstar Communications Limited - Investor Relations Sarah Hollins | +44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.